NVS's Quality Score rose 1 point on Fri, Nov 6, to 14. It closed near its high of the day.
Follow NVS's trial news. Pro members can get an alert when Novartis files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 2% on Oct 27, and still 6% over its Oct 26 close.
“Core operating income was USD 6.0 billion (+11%, +10% cc), mainly driven by higher net sales.”
| The chart | Above every average |
| Latest filing | 6-K, Oct 27 |
Reports Wed Feb 3, before the open
No open-market buys or sales by its officers or directors in their filings of the last year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Above Averagefor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means
NVS is #10 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 10 |
Reports Wed Feb 3, before the open (in 86 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A profit of $0.63 a share.
“Core operating income was USD 6.0 billion (+11%, +10% cc), mainly driven by higher net sales.”
NVS's results filing gives no sales by line in a table we read. Its annual report gives the year's, in About.
| Measure | Figure |
|---|---|
| Core operating income | Expected to be in line to grow low single-digit |
“Net income was USD 7.6 billion (–34%, –35% cc), mainly due to lower operating income, higher interest expense and higher income taxes.”
From its results filing (SEC filing · Oct 27)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 27, 2026 | +0.2% | +2.0% | +5.0% |
| Jul 21, 2026 | +3.9% | +2.9% | +4.4% |
| Apr 28, 2026 | +0.1% | +0.9% | +0.3% |
RSI 64.4, MACD above signal, above both averages. Not scored.
Its dividends come to 51% of its free cash flow.
| Dividend | $4.74 a share a year |
| Paid out | About $9B a year |
| Free cash flow | $18B |
| Record | Raised each of the last 5 years |
3 trades disclosed in the last six months. The newest:
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
NVS scores 14 today, which Breakaway calls Above Average. It is #10 of 90 in Pharma by Quality Score, with 6 of 14 chart checks firing. Up 2% on Oct 27, and still 6% over its Oct 26 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
NVS scores 14 today, which Breakaway calls Above Average (11 to 14). That is #10 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NVS's 14.
Reports Wed Feb 3, before the open, a date the company confirmed. NVS closed higher after 4 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free for 24 hours. No account. No card. Then keep going with a free account.